Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22080754 | 0.87 | SHBG (0.37) | CYP3A4ALDH1A1ESR1ESR2ALOX5 | |
| SCHEMBL28041166 | 0.72 | SHBG (0.46) | CYP3A4ALDH1A1ESR1ESR2CYP1A2 | |
| SCHEMBL24205697 | 0.70 | NPC1 (0.37) | CYP3A4ALDH1A1ESR1ESR2CYP1A2 | |
| SCHEMBL5185716 | 0.69 | CES2 (0.39) | CYP1A2 | |
| SCHEMBL29809621 | 0.69 | CES2 (0.39) | CYP1A2 | |
| SCHEMBL5185713 | 0.69 | CES2 (0.39) | CYP1A2 | |
| SCHEMBL1276281 | 0.68 | ESR1 (0.57) | CYP3A4ALDH1A1ESR1ESR2CYP1A2 | |
| SCHEMBL8369739 | 0.68 | SHBG (0.38) | CYP3A4ALDH1A1ESR1ESR2CYP1A2 | |
| SCHEMBL5143831 | 0.68 | SHBG (0.38) | CYP3A4ALDH1A1ESR1ESR2CYP2C9 | |
| SCHEMBL5185043 | 0.67 | APEX1 (0.37) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017527-A1 | NOVEL PROCEDURE FOR THE FORMATION OF 2H-BENZOTRIAZOLE BODIES AND CONGENERS | BASF SE (DE) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017527-A1 | NOVEL PROCEDURE FOR THE FORMATION OF 2H-BENZOTRIAZOLE BODIES AND CONGENERS | GABBR1, GABBR2, SULT2A1 | CYP3A4 125/4885ALDH1A1 488/4885ESR1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.